The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment

Summary.  Background: Thromboembolism can occur during acute leukemia, especially acute lymphoid leukemia (ALL) treated with l‐asparaginase. Yet, most reports are anecdotical and scarce data are available on the risk of thrombosis in acute myeloid leukemia (AML). Objectives: To evaluate the risk of thrombosis in patients with acute leukemia. Patients and methods: Three‐hundred and seventy‐nine consecutive adult patients with newly diagnosed acute leukemia were recruited in an observational cohort study conducted from January 1994 to December 2003. Diagnosis was ALL in 69 patients, acute promyelocytic leukemia (APL; FAB subtype M3) in 31, and non‐M3 AML in 279. All first or recurrent symptomatic thromboembolic events objectively diagnosed were recorded. Results: Twenty‐four patients of the overall 379 (6.3%; 95% CI 4.1%–9.2%) had a first thrombosis, venous in 80% of the cases and arterial in 20%. At diagnosis, thrombosis was a presenting manifestation in 13 cases (3.4% of the whole cohort): 1.4% in ALL, 9.6% in APL, and 3.2% in non‐M3 AML patients. Follow‐up was carried out on 343 patients without thrombosis at diagnosis and further 11 thrombotic events (3.2%) were recorded. At 6 months from diagnosis, the cumulative incidence of thrombosis was 10.6% in ALL, 8.4% in APL, and 1.7% in non‐M3 AML patients. The patients who received l‐asparaginase had a 4.9‐fold increased risk of thrombosis in comparison with those who did not (95% CI 1.5–16.0). The fatality rate due to thrombosis was 0.8%. Conclusions: In patients with acute leukemia, the risk of thrombosis is not negligible. Thombosis can be a presenting symptom at diagnosis in a significant portion of cases with APL (9.6%) and non‐M3 AML (3.2%); a similar rate of thrombosis can occur during the subsequent course of the disease. The incidence of symptomatic thrombosis at diagnosis is relatively low in ALL patients (1.4%), but is significantly increased by further treatment up to 10.6%. Strategies of antithrombotic prophylaxis should be investigated in this setting.

[1]  D Green,et al.  Effects of all‐trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia , 2004, Journal of thrombosis and haemostasis : JTH.

[2]  E. Cook,et al.  Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Bourhis,et al.  Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.

[4]  M. Voso,et al.  Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre. , 2003, Leukemia & lymphoma.

[5]  M. Gobbi,et al.  Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols , 2003, Leukemia.

[6]  C. Schumann,et al.  Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. , 2003, Blood.

[7]  L. Mitchell.  A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase , 2003 .

[8]  K. Horibe,et al.  Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: A retrospective study by the JACLS , 2002, Pediatrics international : official journal of the Japan Pediatric Society.

[9]  C. Cheung,et al.  Acute myeloid leukaemia presenting as retinal vein occlusion and eyelid swelling , 2002, Eye.

[10]  M. Baccarani,et al.  Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. , 2002, Blood.

[11]  C. Bloomfield,et al.  All-trans-Retinoic Acid in Acute Promyelocytic Leukemia , 2000 .

[12]  A. Falanga,et al.  Molecular basis for the relationship between thrombosis and cancer. , 2001, Thrombosis research.

[13]  M. Baccarani,et al.  Liposomal daunorubicin plus cytosine arabinoside for elderly patients with acute myeloid leukemia: The gimema experience , 2000 .

[14]  Y. Ishikawa,et al.  Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study. , 2000, International journal of hematology.

[15]  D. Körholz,et al.  Low rate of severe venous thromboses in children with ALL treatment according to COALL-92 and -97 protocol , 1999, Klinische Padiatrie.

[16]  R. Junker,et al.  Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. , 1999, Blood.

[17]  R. Pasquini,et al.  Effect of all-trans retinoic acid on newly diagnosed acute promyelocytic leukemia patients: results of a Brazilian center. , 1998, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[18]  T. Barbui,et al.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1997, The New England journal of medicine.

[19]  T. Barbui,et al.  Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy , 1997 .

[20]  M. Kizaki,et al.  Long-term Follow-up of Hemostatic Molecular Markers during Remission Induction Therapy with All-Trans Retinoic Acid for Acute Promyelocytic Leukemia , 1997, Thrombosis and Haemostasis.

[21]  Z. Dreyer,et al.  Renal Venous Thrombosis Complicating Acute Myeloid Leukemia with Hyperleukocytosis , 1996, Journal of pediatric hematology/oncology.

[22]  A. Vekhoff,et al.  Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial , 1996 .

[23]  E. Jaffe,et al.  Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Rutella,et al.  Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. , 1995, Blood.

[25]  T. Barbui,et al.  Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. , 1995, Blood.

[26]  F. Mandelli,et al.  Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L‐asparaginase during induction therapy: A retrospective study , 1992, European journal of haematology.

[27]  M. Haddad,et al.  Recurrent peripheral arterial occlusion by leukemic cells sedimentation in acute promyelocytic leukemia. , 1992, Journal of pediatric surgery.

[28]  C. Bloomfield,et al.  Trisomy 13 in acute leukemia. , 1992, Leukemia & lymphoma.

[29]  A. Hazani,et al.  Acute promyelocytic leukemia presenting as sudden blindness and sinus vein thrombosis , 1988, American journal of hematology.

[30]  R. Simon,et al.  Confidence intervals for reporting results of clinical trials. , 1986, Annals of internal medicine.

[31]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[32]  D. Catovsky,et al.  Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[33]  R. Brinson,et al.  Acute lymphoblastic leukemia manifested as aortic occlusion. , 1984, The American journal of medicine.

[34]  N. Jetha.  Promyelocytic leukemia with multiorgan infarctions and large-vessel thrombosis. , 1981, Archives of pathology & laboratory medicine.

[35]  R. Chillar,et al.  Case report: hepatic vein thrombosis (acute Budd-Chiari syndrome) in acute leukemia. , 1981, The American journal of the medical sciences.

[36]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[37]  I. Peake.  International Society on Thrombosis and Haemostasis , 1974, Thrombosis and Haemostasis.

[38]  U. Jäger,et al.  Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. , 2005, Thrombosis research.

[39]  G. Leone,et al.  Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene. , 2003, Haematologica.

[40]  Giuseppe Leone,et al.  Screening for inherited thrombophilia: indications and therapeutic implications. , 2002, Haematologica.

[41]  L. Mele,et al.  Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. , 2000, Haematologica.

[42]  M. Samama,et al.  Laboratory Diagnosis of the Thrombophilic State in Cancer Patients , 1999, Seminars in thrombosis and hemostasis.

[43]  T. Barbui,et al.  The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. , 1998, Blood.

[44]  T. Barbui,et al.  Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. , 1997, Blood.

[45]  M. Kizaki,et al.  Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS). , 1997, Thrombosis and haemostasis.

[46]  E. Estey,et al.  Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. , 1996, Leukemia & lymphoma.

[47]  H. Dombret,et al.  In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. , 1995, Leukemia.

[48]  M. Andrew,et al.  Hemostasis in Childhood Acute Lymphoblastic Leukemia: Coagulopathy Induced by Disease and Treatment , 1995, Seminars in thrombosis and hemostasis.

[49]  C. Aul,et al.  All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia. , 1992, Blood.

[50]  F. Mandelli,et al.  Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group. , 1992, Leukemia.

[51]  M. Voso,et al.  L-Asparaginase-Induced Coagulopathy in Acute Lymphoblastic Leukemia , 1992 .

[52]  H. Heslop,et al.  Immunotherapy of leukemia. , 1992, Leukemia.

[53]  A. Dario,et al.  Occlusion of the carotid artery as presenting symptom of acute promyelocytic leukemia. , 1991, Schweizer Archiv fur Neurologie und Psychiatrie.